SWTX - SpringWorks Therapeutics Inc Stock Price, Fair Value and News

41.49USD+0.60 (+1.47%)Market Closed

Market Summary

USD41.49+0.60

Market Closed

1.47%

SWTX Alerts

Big jump in Revenue (Y/Y)

Losses in recent quarter

SWTX Stock Price

View Fullscreen

SWTX RSI Chart

SWTX Valuation

Market Cap

3.1B

Price/Earnings (Trailing)

-9.07

Price/Sales (Trailing)

80.83

Price/Free Cashflow

-12.55

SWTX Price/Sales (Trailing)

SWTX Profitability

Return on Equity

-59.75%

Return on Assets

-51.62%

Free Cashflow Yield

-7.97%

SWTX Fundamentals

SWTX Revenue

Revenue (TTM)

38.0M

Rev. Growth (Yr)

264.94%

Rev. Growth (Qtr)

274.91%

SWTX Earnings

Earnings (TTM)

-339.1M

Earnings Growth (Yr)

-19.02%

Earnings Growth (Qtr)

7.35%

Breaking Down SWTX Revenue

Last 7 days

-10.4%

Last 30 days

-2.9%

Last 90 days

-7.2%

Trailing 12 Months

45.1%

How does SWTX drawdown profile look like?

SWTX Financial Health

Current Ratio

6.85

SWTX Investor Care

Shares Dilution (1Y)

18.49%

Diluted EPS (TTM)

-5.15

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	38.0M	0	0	0
2023	11.7M	0	17.0M	21.7M
2022	1.9M	3.3M	4.7M	6.1M
2021	26.4M	17.8M	9.2M	546.0K
2020	0	3.1M	2.2M	35.0M
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of SpringWorks Therapeutics Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Apr 01, 2024	ashar bhavesh	sold (taxes)	-86,858	47.62	-1,824	chief commercial officer
Feb 16, 2024	pichl daniel	sold	-751,550	50.1033	-15,000	chief people officer
Feb 16, 2024	pichl daniel	acquired	414,600	27.64	15,000	chief people officer
Feb 05, 2024	ashar bhavesh	sold	-238,435	49.3245	-4,834	chief commercial officer
Feb 02, 2024	ashar bhavesh	sold	-142,976	44.3749	-3,222	chief commercial officer
Feb 02, 2024	pichl daniel	sold	-1,160,360	44.3208	-26,181	chief people officer
Feb 02, 2024	pichl daniel	acquired	449,150	27.64	16,250	chief people officer
Jan 08, 2024	cassidy james	sold (taxes)	-45,392	41.53	-1,093	chief medical officer
Jan 08, 2024	ashar bhavesh	sold (taxes)	-60,177	41.53	-1,449	chief commercial officer
Jan 08, 2024	weinstein herschel s	sold (taxes)	-100,627	41.53	-2,423	general counsel & secretary

Which funds bought or sold SWTX recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 10, 2024	WELLS FARGO & COMPANY/MN	added	6.4	1,559,020	5,144,520	-%
May 10, 2024	BlackRock Inc.	added	1.05	71,250,800	267,701,000	0.01%
May 10, 2024	GROUP ONE TRADING, L.P.	added	3,794	778,463	793,574	-%
May 10, 2024	MACKENZIE FINANCIAL CORP	new	-	203,623	203,623	-%
May 10, 2024	Rubric Capital Management LP	new	-	21,005,500	21,005,500	0.62%
May 10, 2024	Y-Intercept (Hong Kong) Ltd	sold off	-100	-402,851	-	-%
May 10, 2024	Pacer Advisors, Inc.	new	-	41,049	41,049	-%
May 10, 2024	PNC Financial Services Group, Inc.	added	346	5,131	6,153	-%
May 10, 2024	CIBC Private Wealth Group, LLC	new	-	3,524	3,524	-%
May 10, 2024	Campbell & CO Investment Adviser LLC	added	24.94	332,965	819,218	0.07%

Are Funds Buying or Selling SWTX?

Are funds buying SWTX calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own SWTX

No. of Funds

Unveiling SpringWorks Therapeutics Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Feb 14, 2024	deep track capital, lp	5.53%	4,063,676	SC 13G/A
Feb 14, 2024	ecor1 capital, llc	0%	0	SC 13G/A
Feb 13, 2024	vanguard group inc	8.38%	6,036,542	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G/A
Jan 26, 2024	blackrock inc.	7.5%	5,382,184	SC 13G/A
Jan 23, 2024	state street corp	3.64%	2,619,650	SC 13G/A
Dec 06, 2023	orbimed advisors llc	4.9%	3,567,159	SC 13D/A
May 17, 2023	orbimed advisors llc	6.7%	4,178,588	SC 13D/A
Apr 14, 2023	deep track capital, lp	5.21%	3,254,132	SC 13G
Mar 20, 2023	bc sw, lp	4.9%	3,081,307	SC 13D/A

Recent SEC filings of SpringWorks Therapeutics Inc

View All Filings

Date Filed	Form Type	Document
May 02, 2024	10-Q	Quarterly Report
May 02, 2024	8-K	Current Report
Apr 05, 2024	ARS	ARS
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A
Apr 03, 2024	4	Insider Trading
Mar 01, 2024	144	Notice of Insider Sale Intent
Feb 27, 2024	8-K	Current Report
Feb 27, 2024	10-K	Annual Report
Feb 27, 2024	424B5	Prospectus Filed

Peers (Alternatives to SpringWorks Therapeutics Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	48.2B	6.8B	19.54%	-2.80%	-8.07	7.03	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.0B	2.0B	0.98%	-26.98%	-57.12	9.47	75.20%	68.82%
BMRN	15.3B	2.5B	-12.72%	-14.31%	74.39	6.18	13.74%	186.89%
INCY	12.9B	3.8B	6.98%	-11.75%	17.35	3.43	8.58%	129.81%
MID-CAP
BBIO	5.3B	107.9M	6.22%	110.41%	-9.76	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-16.95%	-51.10%	-12.51	9.96	394.93%	39.61%
AXSM	3.6B	251.0M	9.36%	-4.29%	-12.12	14.31	73.58%	-86.73%
ARWR	2.7B	240.7M	-10.69%	-43.90%	-5.82	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-11.38%	-29.25%	-1.5K	3.08	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	6.64%	20.67%	29.44	4.66	60.38%	-34.49%
NVAX	1.8B	996.6M	206.31%	55.15%	-4.62	1.85	-26.66%	65.49%
CRBP	458.7M	881.7K	5.07%	336.18%	-13.59	481.06	-77.61%	33.36%
INO	294.6M	4.9M	3.08%	29.79%	-2.36	60.54	-54.97%	48.23%
IBIO	15.6M	2.1M	-10.40%	79.21%	-0.67	7.61	-13.45%	69.54%

SpringWorks Therapeutics Inc News

Latest updates

SpringWorks Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																		(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q3	2019Q2
Revenue	274.9%	21,006	5,603	5,662	5,756	4,665	912	372	198	189	179	211	17,028	33,844	63.00	157	936	997	1,004
Costs and Expenses	-	114,937	-	-	77,699	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating Expenses	-	-	-	83,999	77,699	78,454	71,740	69,011	61,469	55,796	40,895	47,021	29,756	23,781	21,592	19,821	16,130	15,329	14,851
S&GA Expenses	0.5%	60,113	59,836	46,546	44,175	40,526	35,673	30,987	27,366	26,452	18,029	14,930	12,381	8,519	7,669	6,874	6,403	4,584	3,646
R&D Expenses	22.8%	53,622	43,652	37,453	33,524	37,928	36,067	38,024	34,103	29,344	22,866	32,091	17,375	15,262	13,923	12,947	9,727	10,745	11,205
Interest Expenses	-	-	-	-	-	1,571	-	-	-	175	-	-	-	333	-	-	-	-	-
Net Income	7.4%	-87,385	-94,322	-79,437	-73,420	-74,178	-72,388	-69,050	-61,801	-56,072	-41,041	-47,010	-29,787	11,272	-21,659	-19,893	-15,294	-16,833	-13,847
Net Income Margin	40.5%	-8.92*	-14.99*	-17.94*	-24.69*	-45.13*	-54.63*	-68.12*	-105.81*	-318.52*	-11.63*	-4.91*	-	-	-	-	-	-	-
Free Cashflow	-31.6%	-79,507	-60,403	-54,083	-64,795	-55,956	-23,132	-41,596	-51,075	-47,820	-27,264	-33,660	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																				(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Assets	-9.5%	657	726	468	517	569	630	682	366	406	452	495	520	555	576	286	301	317	335	348	48.00
Current Assets	-5.8%	472	501	432	484	538	600	657	342	356	383	433	467	482	513	279	294	314	331	345	47.00
Cash Equivalents	-32.6%	119	176	99.00	115	102	67.00	477	70.00	83.00	105	94.00	85.00	96.00	148	85.00	227	312	328	344	46.00
Inventory	68.1%	5.00	3.00	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Net PPE	1.8%	18.00	18.00	21.00	18.00	16.00	14.00	11.00	9.00	6.00	3.00	2.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	1.00	0.00
Liabilities	-10.2%	89.00	100	73.00	66.00	62.00	72.00	69.00	40.00	29.00	30.00	29.00	24.00	20.00	19.00	13.00	10.00	9.00	13.00	11.00	5.00
Current Liabilities	-11.8%	69.00	78.00	50.00	42.00	38.00	51.00	49.00	35.00	23.00	30.00	28.00	23.00	19.00	18.00	13.00	10.00	9.00	12.00	10.00	4.00
Shareholder's Equity	-9.4%	567	626	395	451	507	558	612	326	377	422	467	497	535	557	273	291	308	322	337	-
Retained Earnings	-9.8%	-982	-895	-800	-721	-643	-569	-495	-423	-354	-292	-236	-195	-148	-118	-129	-108	-88.32	-73.03	-56.81	-22.45
Additional Paid-In Capital	2.4%	1,561	1,524	1,200	1,177	1,154	1,130	1,111	752	733	715	703	692	683	676	403	399	396	395	394	1.00
Shares Outstanding	0.8%	74.00	73.00	63.00	63.00	63.00	62.00	50.00	49.00	49.00	48.00	48.00	48.00	-	-	-	-	-	-	-	-
Float	-	-	-	-	1,601	-	-	-	906	-	-	-	2,903	-	-	-	897	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-25.9%	-78,930	-62,705	-50,461	-47,811	-61,818	-54,200	-19,604	-39,071	-48,688	-46,316	-26,929	-33,528	-21,104	15,066	-14,700	-16,159	-16,398	-16,063	-11,113	-13,091	-7,177
Share Based Compensation	21.5%	30,462	25,067	23,098	22,974	23,395	18,924	18,518	18,429	17,094	11,882	10,712	8,795	7,055	3,042	3,043	2,599	1,350	950	788	648	723
Cashflow From Investing	113.5%	21,463	-159,205	34,599	60,756	98,604	-355,010	86,232	26,757	26,424	56,181	35,785	22,544	-30,918	-222,781	-127,563	-68,328	-160	-130	-84.00	-3,785	-261
Cashflow From Financing	-100.2%	-552	299,071	-242	-342	-1,848	298	340,231	-88.00	261	244	425	129	359	269,973	428	78.00	6.00	20.00	169,731	-	163,957
Buy Backs	2468.0%	6,497	253	264	352	1,931	-	212	-	-	-	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

SWTX Income Statement

2024-03-31

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 21,006	$ 0
Operating costs and expenses:
Cost of product revenue	1,202	0
Selling, general and administrative	60,113	44,175
Research and development	53,622	33,524
Total operating costs and expenses	114,937	77,699
Loss from operations	(93,931)	(77,699)
Interest and other income:
Interest and other income, net	7,571	5,557
Total interest and other income	7,571	5,557
Equity method investment loss	(1,025)	(1,278)
Net loss	$ (87,385)	$ (73,420)
Net loss per share, basic (usd per share)	$ (1.18)	$ (1.18)
Net loss per share, diluted (usd per share)	$ (1.18)	$ (1.18)
Weighted average common shares outstanding, basic (in shares)	73,768,603	62,326,992
Weighted average common shares outstanding, diluted (in shares)	73,768,603	62,326,992
Revenue from Contract with Customer, Product and Service [Extensible Enumeration]	Product [Member]	Product [Member]

SWTX Balance Sheet

2024-03-31

Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 118,031	$ 176,053
Marketable securities	318,552	303,149
Accounts receivable, net	15,529	5,930
Inventory	5,216	3,103
Prepaid expenses and other current assets	14,470	12,677
Total current assets	471,798	500,912
Long-term marketable securities	136,404	183,386
Property and equipment, net	18,263	17,943
Operating lease right-of-use assets	5,817	6,144
Equity method investment	9,165	1,955
Restricted cash	616	613
Other assets	14,769	14,835
Total assets	656,832	725,788
Current liabilities:
Accounts payable	7,011	7,396
Accrued expenses	56,273	65,569
Operating lease liabilities, current	981	1,061
Deferred revenue, current	4,652	4,144
Total current liabilities	68,917	78,170
Operating lease liabilities, long-term	5,581	5,996
Deferred revenue, long-term	14,894	15,403
Total liabilities	89,392	99,569
Commitments and contingencies
Stockholders’ equity:
Preferred stock, $0.0001 par value, 10,000,000 shares authorized, no shares issued or outstanding at March 31, 2024 and December 31, 2023.	0	0
Common stock, $0.0001 par value, 150,000,000 shares authorized, 74,355,487 and 73,620,361 shares issued, and 74,061,196 and 73,486,699 shares outstanding at March 31, 2024 and December 31, 2023, respectively.	7	7
Additional paid-in capital	1,560,603	1,524,196
Accumulated deficit	(982,419)	(895,034)
Treasury stock, at cost (160,629 and 133,662 shares of common stock at March 31, 2024 and December 31, 2023, respectively).	(10,638)	(4,141)
Accumulated other comprehensive (loss) income	(113)	1,191
Total stockholders’ equity	567,440	626,219
Total liabilities and stockholders’ equity	$ 656,832	$ 725,788

About SpringWorks Therapeutics Inc

SpringWorks Therapeutics, Inc. acquires, develops, and commercializes medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is nirogacestat, an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors. The company is also developing mirdametinib, an oral small molecule MEK inhibitor that is in Phase 2b clinical trials for the treatment of neurofibromatosis type 1-associated plexiform neurofibromas, as well as Phase 1/2a clinical trial for the treatment of NF1-PN; mirdametinib + lifirafenib, a combination therapy that is in Phase 1b/2 clinical trial in patients with advanced or refractory solid tumors; and mirdametinib in monotherapy and combination approaches to treat solid tumors. In addition, it develops BGB-3245, an oral selective small molecule inhibitor of monomeric and dimeric forms of activating BRAF mutations. The company has collaborations with BeiGene, Ltd. and GlaxoSmithKline LLC; and license agreements with Pfizer Inc. for nirogacestat and mirdametinib. It also has a license agreement with Katholieke Universiteit Leuven and the Flanders Institute for Biotechnology for a portfolio of novel small molecule inhibitors of the TEA Domain; and Dana-Farber Cancer Institute for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor. The company was founded in 2017 and is headquartered in Stamford, Connecticut.

CEO	Mr. Saqib Islam J.D.
WEBSITE	springworkstx.com
INDUSTRY	Biotechnology
EMPLOYEES	227

SpringWorks Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for SpringWorks Therapeutics Inc? What does SWTX stand for in stocks?

SWTX is the stock ticker symbol of SpringWorks Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of SpringWorks Therapeutics Inc (SWTX)?

As of Mon May 13 2024, market cap of SpringWorks Therapeutics Inc is 3.07 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of SWTX stock?

You can check SWTX's fair value in chart for subscribers.

What is the fair value of SWTX stock?

You can check SWTX's fair value in chart for subscribers. The fair value of SpringWorks Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of SpringWorks Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for SWTX so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is SpringWorks Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether SWTX is over valued or under valued. Whether SpringWorks Therapeutics Inc is cheap or expensive depends on the assumptions which impact SpringWorks Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for SWTX.

What is SpringWorks Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon May 13 2024, SWTX's PE ratio (Price to Earnings) is -9.07 and Price to Sales (PS) ratio is 80.83. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. SWTX PE ratio will change depending on the future growth rate expectations of investors.